Sarilumab: First Global Approval
Sign Up to like & getrecommendations! Published in 2017 at "Drugs"
DOI: 10.1007/s40265-017-0724-2
Abstract: Sarilumab (Kevzara™) is a fully human IgG1 monoclonal antibody that binds specifically to both soluble and membrane-bound interleukin (IL)-6 receptors (sIL-6Rα and mIL-6Rα) and thereby inhibits IL-6-mediated signalling through these receptors. Subcutaneous sarilumab is approved… read more here.
Keywords: global approval; sarilumab; first global; rheumatoid arthritis ... See more keywords
Sarilumab: A Review in Moderate to Severe Rheumatoid Arthritis
Sign Up to like & getrecommendations! Published in 2018 at "Drugs"
DOI: 10.1007/s40265-018-0929-z
Abstract: Sarilumab (Kevzara®), a monoclonal antibody against the interleukin-6 (IL-6) receptor, is approved in various countries, including the USA, those of the EU, and Japan, as a subcutaneous treatment administered every 2 weeks for moderately to severely… read more here.
Keywords: review moderate; sarilumab review; sarilumab; rheumatoid arthritis ... See more keywords
Lessons learned from the preclinical discovery and development of sarilumab for the treatment of rheumatoid arthritis
Sign Up to like & getrecommendations! Published in 2022 at "Expert Opinion on Drug Discovery"
DOI: 10.1080/17460441.2022.2093852
Abstract: ABSTRACT Introduction Rheumatoid arthritis (RA) pathogenesis is driven by a complex network of proinflammatory cytokines, among which interleukin-6 (IL-6) plays a key role in inducing and perpetuating chronic inflammation. Targeting the IL-6 pathway has shown… read more here.
Keywords: sarilumab treatment; treatment; sarilumab; rheumatoid arthritis ... See more keywords
Pharmacokinetics, Pharmacodynamics and Safety of Single-Dose Subcutaneous Sarilumab With or Without Methotrexate in Japanese Patients with Rheumatoid Arthritis: Two Single-Dose Studies.
Sign Up to like & getrecommendations! Published in 2022 at "Modern rheumatology"
DOI: 10.1093/mr/roac036
Abstract: OBJECTIVES To assess safety and pharmacokinetics (PK) of single-dose subcutaneous (SC) sarilumab or tocilizumab SC ± methotrexate; to assess pharmacodynamics (PD) of sarilumab SC or tocilizumab SC monotherapy in Japanese rheumatoid arthritis (RA) patients. METHODS… read more here.
Keywords: single dose; sarilumab; subcutaneous sarilumab; rheumatoid arthritis ... See more keywords
Long-term safety and efficacy of sarilumab with or without background csDMARDs in rheumatoid arthritis.
Sign Up to like & getrecommendations! Published in 2023 at "Rheumatology"
DOI: 10.1093/rheumatology/kead062
Abstract: OBJECTIVE To evaluate the long-term safety and efficacy of sarilumab with/without conventional synthetic (cs) DMARDs in RA. METHODS The analyses evaluated two open-label extensions (OLEs): EXTEND and MONARCH OLE, which included patients from six randomized… read more here.
Keywords: long term; safety; efficacy; group ... See more keywords
Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial
Sign Up to like & getrecommendations! Published in 2017 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2016-210310
Abstract: Objectives To compare efficacy and safety of sarilumab monotherapy with adalimumab monotherapy in patients with active rheumatoid arthritis (RA) who should not continue treatment with methotrexate (MTX) due to intolerance or inadequate response. Methods MONARCH… read more here.
Keywords: treatment; safety; sarilumab monotherapy; sarilumab ... See more keywords
SAT0172 Long-term efficacy with 5-year-radiographic results and safety of sarilumab in combination with csdmards in patients with rheumatoid arthritis
Sign Up to like & getrecommendations! Published in 2018 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2018-eular.1373
Abstract: Background: Long-term data are being collected on sarilumab in combination with csDMARDs in patients with RA originally enrolled in six trials (TARGET, NCT01709578; MOBILITY, NCT01061736; NCT01764997; NCT01768572; NCT02057250; NCT01217814) including those who continued into extension… read more here.
Keywords: sanofi; pfizer; treatment; safety ... See more keywords
SAT0121 EFFECT OF SARILUMAB ON GLYCOSYLATED HEMOGLOBIN IN PATIENTS WITH RHEUMATOID ARTHRITIS AND DIABETES
Sign Up to like & getrecommendations! Published in 2019 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2019-eular.3259
Abstract: Background Sarilumab is a human mAb blocking the IL-6Rα, approved for adult patients with moderately to severely active RA. The incidence of Type 2 diabetes is increased in patients with RA, and elevated IL-6 may… read more here.
Keywords: sanofi; sanofi genzyme; sarilumab; glycosylated hemoglobin ... See more keywords
Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: A pragmatic, embedded randomized clinical trial
Sign Up to like & getrecommendations! Published in 2022 at "PLoS ONE"
DOI: 10.1371/journal.pone.0263591
Abstract: Importance and objective The aim of this pragmatic, embedded, adaptive trial was to measure the effectiveness of the subcutaneous anti-IL-6R antibody sarilumab, when added to an evolving standard of care (SOC), for clinical management of… read more here.
Keywords: hospitalized patients; pragmatic embedded; subcutaneous sarilumab; trial ... See more keywords